VXRT:OTCMKTS
Vaxart Inc
0,44 $
arrow_downward
−0,68%(−0,0030) 1D
2. okt., 16:00:00 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za VXRT …
Odpri
0,45 $
Visoka
0,46 $
Nizka
0,43 $
Tržna kapitalizacija
106,12 mio.
Povprečni promet
270,35 tis.
Promet
239,38 tis.
Razmerje med ceno delnice in čistim dobičkom
2,68
52-tedenski najvišji tečaj
0,84 $
52-tedenski najnižji tečaj
0,30 $
Čisti dobiček na delnico
0,16 $
Beta
1,05
Št. izdanih delnic
242,84 mio.
Št. zaposlenih
65
Odpri
0,45 $
Visoka
0,46 $
Nizka
0,43 $
Tržna kapitalizacija
106,12 mio.
Povprečni promet
270,35 tis.
Promet
239,38 tis.
Razmerje med ceno delnice in čistim dobičkom
2,68
52-tedenski najvišji tečaj
0,84 $
52-tedenski najnižji tečaj
0,30 $
Čisti dobiček na delnico
0,16 $
Beta
1,05
Št. izdanih delnic
242,84 mio.
Št. zaposlenih
65
Novice
Iz spletnih virov in novičarskih partnerjev
marketscreener.com
·
pred 7 minutami
Vertical Aerospace Receives NYSE Noncompliance Notice
Intellia Therapeutics
·
pred 55 minutami
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
·
pred 42 minutami
NeuroSense Provides Update on Nasdaq Listing Compliance
Investor's Business Daily
·
pred 7 minutami
Nasdaq Pops After Jobs Report; Arrow, Materion, Advantest In Focus
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Vizitka: Vaxart Inc
Generalni direktor-
Št. zaposlenih65
Ustanovljenomar. 2004
SedežSouth San Francisco, Kalifornija, Združene države Amerike
Sektor-
Spletno mestovaxart.com